147 related articles for article (PubMed ID: 37407093)
1. The Role of Coproporphyrins As Endogenous Biomarkers for Organic Anion Transporting Polypeptide 1B Inhibition-Progress from 2016 to 2023.
Lai Y
Drug Metab Dispos; 2023 Aug; 51(8):950-961. PubMed ID: 37407093
[TBL] [Abstract][Full Text] [Related]
2. Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition.
Shen H; Christopher L; Lai Y; Gong J; Kandoussi H; Garonzik S; Perera V; Garimella T; Humphreys WG
Drug Metab Dispos; 2018 Aug; 46(8):1075-1082. PubMed ID: 29777022
[TBL] [Abstract][Full Text] [Related]
3. Further Evaluation of Coproporphyrins as Clinical Endogenous Markers for OATP1B.
Feng S; Bo Q; Coleman HA; Charoin JE; Zhu M; Xiao J; Jin Y
J Clin Pharmacol; 2021 Aug; 61(8):1027-1034. PubMed ID: 33460165
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Selectivity of Several Organic Anion Transporting Polypeptide 1B Biomarkers Using Relative Activity Factor Method.
Chan GH; Houle R; Zhang J; Katwaru R; Li Y; Chu X
Drug Metab Dispos; 2023 Sep; 51(9):1089-1104. PubMed ID: 37137718
[TBL] [Abstract][Full Text] [Related]
5. Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects.
Shen H; Chen W; Drexler DM; Mandlekar S; Holenarsipur VK; Shields EE; Langish R; Sidik K; Gan J; Humphreys WG; Marathe P; Lai Y
Drug Metab Dispos; 2017 Aug; 45(8):908-919. PubMed ID: 28576766
[TBL] [Abstract][Full Text] [Related]
6. Utilization of OATP1B Biomarker Coproporphyrin-I to Guide Drug-Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry.
Kikuchi R; Chothe PP; Chu X; Huth F; Ishida K; Ishiguro N; Jiang R; Shen H; Stahl SH; Varma MVS; Willemin ME; Morse BL
Clin Pharmacol Ther; 2023 Dec; 114(6):1170-1183. PubMed ID: 37750401
[TBL] [Abstract][Full Text] [Related]
7. Cluster Gauss-Newton method analyses of PBPK model parameter combinations of coproporphyrin-I based on OATP1B-mediated rifampicin interaction studies.
Yoshikado T; Aoki Y; Mochizuki T; Rodrigues AD; Chiba K; Kusuhara H; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1341-1357. PubMed ID: 35945914
[TBL] [Abstract][Full Text] [Related]
8. Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition.
Lai Y; Mandlekar S; Shen H; Holenarsipur VK; Langish R; Rajanna P; Murugesan S; Gaud N; Selvam S; Date O; Cheng Y; Shipkova P; Dai J; Humphreys WG; Marathe P
J Pharmacol Exp Ther; 2016 Sep; 358(3):397-404. PubMed ID: 27317801
[TBL] [Abstract][Full Text] [Related]
9. Rifampin- and Silymarin-Mediated Pharmacokinetic Interactions of Exogenous and Endogenous Substrates in a Transgenic OATP1B Mouse Model.
Bechtold BJ; Lynch KD; Oyanna VO; Call MR; Graf TN; Oberlies NH; Clarke JD
Mol Pharm; 2024 May; 21(5):2284-2297. PubMed ID: 38529622
[TBL] [Abstract][Full Text] [Related]
10. Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition.
Gu X; Wang L; Gan J; Fancher RM; Tian Y; Hong Y; Lai Y; Sinz M; Shen H
Drug Metab Dispos; 2020 Aug; 48(8):724-734. PubMed ID: 32482623
[TBL] [Abstract][Full Text] [Related]
11. Repression of Organic Anion Transporting Polypeptide (OATP) 1B Expression and Increase of Plasma Coproporphyrin Level as Evidence for OATP1B Downregulation in Cynomolgus Monkeys Treated with Chenodeoxycholic Acid.
Zhang Y; Chen SJ; Chen C; Chen XQ; Chatterjee S; Shuster DJ; Dexter H; Armstrong L; Joshi EM; Yang Z; Shen H
Drug Metab Dispos; 2022 Aug; 50(8):1077-1086. PubMed ID: 35636769
[TBL] [Abstract][Full Text] [Related]
12. Quantitative prediction of OATP1B-mediated drug-drug interactions using endogenous biomarker coproporphyrin I.
Takubo H; Bessho K; Watari R; Shigemi R
Xenobiotica; 2022 Apr; 52(4):397-404. PubMed ID: 35638858
[TBL] [Abstract][Full Text] [Related]
13. Development of an LC-MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions.
Njumbe Ediage E; Dillen L; Vroman A; Diels L; Kunze A; Snoeys J; Verhaeghe T
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1073():80-89. PubMed ID: 29241088
[TBL] [Abstract][Full Text] [Related]
14. Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions.
Kimoto E; Costales C; West MA; Bi YA; Vourvahis M; David Rodrigues A; Varma MVS
Clin Pharmacol Ther; 2022 Feb; 111(2):404-415. PubMed ID: 34605015
[TBL] [Abstract][Full Text] [Related]
15. Organic Anion-Transporting Polypeptide Genes Are Not Induced by the Pregnane X Receptor Activator Rifampin: Studies in Hepatocytes In Vitro and in Monkeys In Vivo.
Niu C; Wang Y; Zhao X; Tep S; Murakami E; Subramanian R; Smith B; Lai Y
Drug Metab Dispos; 2019 Dec; 47(12):1433-1442. PubMed ID: 31582395
[TBL] [Abstract][Full Text] [Related]
16. Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug-Drug Interactions.
Kunze A; Ediage EN; Dillen L; Monshouwer M; Snoeys J
Clin Pharmacokinet; 2018 Dec; 57(12):1559-1570. PubMed ID: 29663259
[TBL] [Abstract][Full Text] [Related]
17. Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species.
Shen H; Dai J; Liu T; Cheng Y; Chen W; Freeden C; Zhang Y; Humphreys WG; Marathe P; Lai Y
J Pharmacol Exp Ther; 2016 May; 357(2):382-93. PubMed ID: 26907622
[TBL] [Abstract][Full Text] [Related]
18. Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III.
Bednarczyk D; Boiselle C
Xenobiotica; 2016; 46(5):457-66. PubMed ID: 26383540
[TBL] [Abstract][Full Text] [Related]
19. UHPLC-MS/MS bioanalysis of human plasma coproporphyrins as potential biomarkers for organic anion-transporting polypeptide-mediated drug interactions.
Kandoussi H; Zeng J; Shah K; Paterson P; Santockyte R; Kadiyala P; Shen H; Shipkova P; Langish R; Burrrell R; Easter J; Mariannino T; Marathe P; Lai Y; Zhang Y; Pillutla R
Bioanalysis; 2018 May; 10(9):633-644. PubMed ID: 29749254
[TBL] [Abstract][Full Text] [Related]
20. GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study.
Cheung KWK; Yoshida K; Cheeti S; Chen B; Morley R; Chan IT; Sahasranaman S; Liu L
Drug Metab Dispos; 2019 Sep; 47(9):966-973. PubMed ID: 31266752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]